OBJECTIVES: To evaluate hepatitis A (HAV) endemicity in six countries via systematic review of published literature. The countries represent varying seroprevalence (different stages of the HAV epidemiologic transition), stages of vaccine consideration, and face different circumstances that may affect vaccine adoption.  METHODS: Articles published from 1990 to October 2011 were identified through a number of article search engines, including PubMed®. Search terms were “Hepatitis A” and [Country]. Reference lists of identified articles were reviewed for relevant articles published prior to 1990. A supplementary Internet search identified additional information not indexed in the reviewed search engines. Articles were excluded if they focused on the biological mechanisms of hepatitis A, were non-human studies, vaccine trial results, case studies or opinion pieces. RESULTS: A total of 797 articles were identified. After exclusions, the number of articles reviewed were: Chile, 33; India, 80; Mexico, 25; Russia, 38; South Korea, 75; and Taiwan, 65. India is still considered to have high HAV endemicity, while Chile and Mexico are intermediate, and Korea, Russia, and Taiwan are low. The timeframe of available data differed greatly by country and often region/city within a country, with some regions only having data as recent as five (in Mexico, Taiwan) or ten (in Chile, India, Russia) years ago. Data supporting the HAV epidemiologic transition varied by country, and it was often unclear at which point the country transitioned to a lower endemicity category, if at all. Hepatitis A incidence data were sparse for some countries, and recent outbreaks were reported in Korea and Taiwan. CONCLUSIONS: Data gaps, including determination of the HAV epidemiologic transition, exist to some extent in all the countries studied.  Filling these data gaps to enhance knowledge of the burden of HAV will assist countries in decision-making regarding vaccine adoption.